A role for the CaM Kinase II related anchoring protein (αkap) in maintaining the stability of nicotinic Acetylcholine Receptors

Chakib Mouslim*, Mohamed Aittaleb*, Richard I. Hume, and Mohammed Akaaboune
1Department of Molecular, Cellular and Developmental Biology, University of Michigan, Ann Arbor, Michigan

Abstract

αkap, a muscle specific anchoring protein encoded within the Camk2a gene is thought to play a role in targeting multiple calcium/calmodulin kinase II isoforms to specific subcellular locations. Here we demonstrate a novel function of αkap in stabilizing nicotinic acetylcholine receptors (AChR). Knockdown of αkap expression with shRNA significantly enhanced the degradation of AChR α-subunits (AChRα), leading to fewer and smaller AChR clusters on the surface of differentiated C2C12 myotubes. Mutagenesis and biochemical studies in HEK293T cells revealed that αkap promoted AChRα stability by a ubiquitin-dependent mechanism. In the absence of αkap, AChRα was heavily ubiquitinated and the number of AChRα was increased by proteasome inhibitors. However, in the presence of αkap, AChRα was less ubiquitinated and proteasome inhibitors had almost no effect on AChRα accumulation. The major sites of AChRα ubiquitination reside within the large intracellular loop and mutations of critical lysine residues in this loop to arginine increased AChRα stability in the absence of αkap. These results provide an unexpected mechanism by which αkap controls receptor trafficking onto the surface of muscle cells, and thus the maintenance of postsynaptic receptor density and synaptic function.

Introduction

The clustering of nicotinic acetylcholine receptors (AChR) at the postsynaptic membrane is a hallmark of the neuromuscular junction (Sanes and Lichtman, 2001). The initial steps involved in the formation of receptor clusters have been extensively studied and several key components of this multi-step process have been identified. Based on mouse genetics studies, MUSK (muscle specific tyrosine kinase), LRP4 (Low-density lipoprotein receptor-related protein 4), rapsyn, and Dok 7 (Dedicator of cytokinesis family member 7) all have been shown to be required for the initial formation of receptor clusters (Gautam et al., 1995; DeChiara et al., 1996; Sanes and Lichtman, 2001; Okada et al., 2006; Weatherbee et al., 2006; Kim et al., 2008; Zhang et al., 2008; Wu et al., 2010). Components of the dystrophin glycoprotein complex have also been shown to be involved in clustering and in the maintenance of postsynaptic receptor density. For example, mice deficient in α-dystrobrevin or α-syntrophin exhibit dramatic reductions in AChR number and density and an abnormal

Address correspondence to: Mohammed Akaaboune, Department of Molecular, Cellular and Developmental Biology, 830 North University Avenue, Ann Arbor, MI 48109, Tel: (834) 648-8512, Fax: (834) 648-0884, makaabou@umich.edu.*Contributed equally to this work

Conflict of interest: No.

Author contributions:
Overall supervision of the study: Mohammed Akaaboune
Designed the experiments and analysis: Chakib Mouslim, Richard Hume, and Mohammed Akaaboune
Performed biochemical and imaging experiments and made reagents: Chakib Mouslim and Mohamed Aittaleb
Performed electrophysiology experiments: Richard Hume
Carried out data analysis and wrote the paper: Chakib Mouslim, Richard Hume, and Mohammed Akaaboune
pattern of receptor clustering (Adams et al., 2000; Grady et al., 2000; Martinez-Pena y Valenzuela et al., 2011).

The maintenance of a high density of AChR in the postsynaptic membrane may also depend on the mechanisms that regulate their progression through the secretory pathway from the endoplasmic reticulum (ER) to the cell surface. However, the molecular machinery that controls the processing of AChR within the secretory pathway remains poorly defined. In an effort to understand the machinery involved in AChR trafficking, we used a multidisciplinary approach that led us to identify a novel function for αkap, a protein previously implicated in localizing multiple isoforms of calcium/calmodulin-dependent protein kinase II (CaMK-II). αkap is a muscle-specific protein encoded within the Camk2a gene that contains a putative transmembrane domain and an association domain, but lacks the catalytic domain that is responsible for the kinase activity of CaMK-II subunit alpha (Bayer et al., 1996; Bayer et al., 1998 Bayer et al., 2002). In skeletal and cardiac muscles, it is thought that αkap is involved in targeting CaMK-II isoforms to the sarcoplasmic reticulum where they regulate calcium homeostasis (Campbell and MacLennan, 1982; Chu et al., 1990; Wang and Best, 1992; Xu et al., 1993; Hain et al., 1995; Pawson and Scott, 1997; Bayer et al., 1998; Nori et al., 2003). In mammalian muscle cells, at least three isoforms of CaMK-I I (βm, γ and δ) have been found to be expressed (Damiani et al., 1995; Bayer et al., 1998) and concentrated at the NMJs (Martinez-Pena y Valenzuela et al., 2010). In the present study, we investigated the role of αkap in muscle cells by knocking down its expression with shRNA and discovered that αkap has a novel function, regulating the degradation of AChR protein.

Materials and Methods

Plasmid constructs

Plasmids containing mouse AChR subunit cDNAs driven by the CMV promoter were a generous gift from Dr. William Green (University of Chicago), Lrp4 cDNA was a generous gift from Dr. Stephan Kröger (University of Munich, Germany). Throughout the paper, the respective subunits are referred to as AChRα, AChRβ, AChRδ and AChRe. The HA-αkap construct was a generous gift from Dr. Ulrich Bayer (University of Colorado). GFP-αkap was generated using the following primers: 5'-GGAATTCTATGCTGCTCTTTCTCACGCTGTGG and 5'GGGTACCATGCGGCAGGAGGGCGCCCCAGATCTGTG and cloned into the pEGFP-C3 vector, in which alanine was mutated to lysine at position 207 (A207K) to prevent the dimerization of GFP (monomeric-GFP-C3)

A plasmid encoding mouse protein disulfide isomerase associated protein 3 (pdiA3) cDNA was purchased from Origen (Origen, MC200134) and subcloned into the mCherry-C1 vector (Clontech, Mountain View, CA) using the following primers: 5'-GGGAATTCTATGCGCTTCAGCTGCCTAGC and 5'-GGGGTACCTAGAGGTCCTCTTGTGCC.

Mutations of lysine residues (K359, 347, 388 and 393) to arginine within the intracellular loop of AChRα were generated using the QuickChange XL Site-directed mutagenesis Kit (Stratagene). The following primers were used for mutagenesis:

359F:5'-CTATGTCTTCTCTGTTTTATCTTCTCTTTGATGGTC
359R:5'-GACCATCCAGAGATAAACAAGAGAAGGATTTTTACAGAAGACATAG
374F:5'-GATATATCTGACATCTCTGGGAGACCGGGTCCTCCTCTGGCC

J Neurosci. Author manuscript; available in PMC 2012 October 11.
374R: 5'-GCCCATAGGTGGAGGCAGAGATGTCAGATATATC
388F: 5'-GGCTTTCACTCTCCGCTGATCAGACACCCTGAGGTGAAAAGCGCC
388R: 5'-GGCGCTTTTCACCTCAGGGTGTCTGATCAGCGGAGAGTGAAAGCC
393F: 5'-CACCCTGAGGTAGGAGCGCCATCGAGGGG
393R: 5'-CCCCTCGATGGCCGCTCCTCACCTCACCTAGGGTG

Two shRNA constructs against murine αkap were generated by cloning the annealed target sequences (nucleotide starting position at either 137 or 337) into BglII/HindIII sites of the pSUPER vector or pSUPER.Neo.GFP according to the manufacturer's recommendations. The target sequence of the shRNA to αkap at position 137 is 5'-GTTCAGTTAATGGAATCTTC and at position 337 is 5'-GGCCTGGACTTTCATCGATTC. A scrambled shRNA (as negative control) was also generated: 5'-GGTTATCTATTAGCGATTCTA. All shRNA constructs were verified by DNA sequencing.

Cell culture and transfection

The C2C12 muscle cell line and the HEK293T human embryonic kidney cell line were purchased from the American Type Culture Collection (Manassas, VA, USA). HEK293T cells were grown at 37 °C in 5% CO2 and maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% (v/v) fetal bovine serum (FBS) (Invitrogen) and 1% Penicillin/Streptomycin. C2C12 myoblasts were maintained in DMEM supplemented with 20% FBS and switched to DMEM with 5% Horse serum (Invitrogen) when cell density reached confluency of about 90%. For AChR staining, C2C12 cells were grown on dishes coated with laminin (to promote the formation of large receptor clusters).

All transfections were performed using Lipofectamine 2000 (Invitrogen) as per manufacturer's recommendation with minor modifications. C2C12 transfection was performed in serum free medium for 8 hours before switching cells to the differentiation medium. HEK293T cells were either harvested for immunoblotting or fixed for confocal imaging 40 to 48 hours after transfection.

Pharmacological agents

The proteasome inhibitor MG132 was purchased from Enzo Life Sciences (Sciences, Plymouth Meeting, PA) and was used at 5 µM. Leupeptin, lactacystin and chloroquine were purchased from Sigma/Aldrich (St. Louis, MO) and used at 20 µg/ml, 10 µg/ml, and 25 µg/ml respectively.

Acetylcholine Chloride (Sigma) was made as a 1 M stock solution in distilled water and kept frozen. On the day of recording, it was diluted to the concentration of choice in extracellular recording solution.

RT-PCR

Total RNA was isolated from cultured myotubes using the RNAeasy Mini Kit (QIAGEN Sciences, Maryland). cDNA was synthesized using Superscript First strand System and oligo (dT) primers (Invitrogen, CA). PCR was performed using the following primers: AChRα: 5'-ACGGCGACTTTGCACTGATC and 5'-CAGGCGCTGACGAGGAGGT; GAPDH: 5'-TGAAGGTGCTGTCGAGAAGGTGC and 5'-CATCTAGCCACCGGAGGGGGG

RT-PCR products were analyzed from samples collected in the exponential phase of amplification (35 cycles for AChR and 30 cycles for GAPDH).
Immunofluorescence and confocal microscopy

To assess AChR clustering, C2C12 myoblasts grown on laminin coated dishes were transfected with 4 µg of pSuper.GFP expressing scrambled shRNA or shRNA(αkap). Eight hours after transfection, myoblasts were transferred into differentiation medium. Four to five days later myotubes were bathed with α-bungarotoxin (α-BTX) conjugated to Alexa594 (BTX-Alexa594) (Invitrogen) at 4 °C for 1 hour, washed in PBS, and then fixed in 2% Paraformaldehyde (PFA). Cells were washed with PBS and mounted in DAPI Prolong Gold anti-fade medium (Invitrogen) and imaged with a Leica SP5 confocal microscope. The z-stacks were then collapsed and the contrast adjusted with Photoshop.

To compare the proportion of the myotube surface covered by AChR clusters under control conditions and when αkap was knocked down, we identified fields in dishes transfected with pSuper.GFP-shRNA(αkap) in which there were both green fluorescent (transfected) and untransfected control myotubes, and then used functions in ImageJ (Version 1.45i) to quantify the extent of clustering. We first applied a binary threshold to the entire red image (BTX-Alexa594), so that all regions with intensity below the threshold (background autofluorescence and fluorescence due to non-clustered receptors) were assigned to white, and the higher intensity regions of clustered receptors were assigned to black. We then outlined at least one fluorescent and one nonfluorescent myotube on the green image (EGFP), and overlaid these regions of interest onto the thresholded images of AChR. We then applied the histogram function to each region of interest to get the number of pixels that were black or white. Finally, we calculated the proportion of each myotube covered by clustered receptors as (number of black pixels)/(total number of pixels in the region of interest).

To assess the localization of AChRα within HEK293T cells, cells were co-transfected with plasmids expressing GFP-αkap, AChRα, and pdIA3-mcherry. 40 to 48 hours later cells were washed with PBS and fixed in 4% PFA for 10 min at room temperature, then bathed in a blocking solution (10% BSA) for 15 minutes, and permeabilized with a solution containing 0.2% Triton X-100 and 2% BSA in PBS for 15 minutes. Cells were incubated overnight with primary monoclonal anti-AChRα antibody MAb35 (The Developmental Studies Hybridoma Bank, Iowa) diluted at 1/1000. Alexa647-conjugated anti-mouse secondary antibody (Jackson ImmunoResearch) was added to cells for 1 h. Cover slips were mounted onto glass slides using DAPI-Prolong Gold antifade medium (Invitrogen) and imaged at the appropriate wavelengths with a Leica SP5 confocal microscope.

Immunoprecipitation, pull down and western blotting

Transfected and untransfected C2C12 myotubes or HEK293T cells were lysed in buffer containing 50 mM HEPES, 300 mM NaCl, 2 mM EDTA, 0.5% NP-40, 0.8% CHAPS, 1 mM PMSF, 2 mM activated sodium orthovanadate, 5 mM NaF and protease inhibitors. Lysates were incubated for 1 hour at 4 °C and cleared by centrifugation. Each lysate was assayed for anti-tubulin reactivity to assess the amount of protein present, and then aliquots of each lysate were typically used for several different procedures.

To selectively pull down surface AChR, living myotubes (untransfected or transfected with or without akap shRNA) were incubated with BTX-biotin for 1 hour at 4 °C. Cells were then lysed and lysates were incubated with NeutrAvidin beads (Fisher Scientific) overnight. To selectively pull down intracellular AChR, living myotubes were bathed with unlabeled BTX to saturate all surface receptors for 1 hour at 4 °C. Cells were then lysed and lysates were incubated with BTX-biotin followed by NeutrAvidin beads overnight. To pull down total AChR, cells were lysed with no pretreatment, and then lysates were incubated with BTX-biotin followed by NeutrAvidin beads overnight. For all three conditions, the beads...
were collected by centrifugation and washed in PBS four times. The bound proteins were released by boiling in reducing 2X LDS buffer (Invitrogen).

To pull down CaMK-IIIs, muscle cell lysates were incubated overnight with Calmodulin beads (Sigma) in the presence of 2 mM CaCl$_2$. The beads were collected and washed four times with buffer containing 0.5% NP40. Because αkap is known to bind to multiple CaMK-II isoforms, this procedure was expected to pull down αkap, even though it lacks a calmodulin binding domain.

The ProFound Mammalian HA-tag IP/Co-IP Kit (Fischer, PA) was used to examine αkap and AChRα interaction in HEK293T cells following the manufacturer’s instructions in the presence of 300 mM NaCl in the M-PER Mammalian Protein extraction reagent. The immunoprecipitate was then probed with anti-HA (Covance) or anti-αkap (Santa Cruz biotechnology) and anti-AChRα (MAB210, Covance) antibodies.

To assay AChR ubiquitination, HEK293T cells were co-transfected with αkap, HA-tagged ubiquitin (HA-Ub) and either wild-type or mutated AChRα constructs (see above). The cells were harvested and lysed in denaturing buffer (50 mM Tris HCl, 150 mM NaCl, 2 mM EDTA, 5 mM N-ethylmaleimide (NEM) (Sigma), 2 mM activated Sodium orthovanadate, 2% SDS and protease inhibitors), boiled for 10 minutes and briefly sonicated. The lysates were diluted to 0.1% SDS using buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP40, 1 mM PMSF, 2 mM activated Sodium orthovanadate, 5 mM NaF and protease inhibitors). Precleared protein lysates (20 µg) were incubated with 2 µg of anti-AChRα (MAB 153, Santa Cruz biotechnology, CA) for 1 hour at 4 °C, followed by additional incubation with 20 µl of Protein A/G Plus-agarose beads (Santa Cruz biotechnology, CA) overnight at 4°C. Beads were collected by centrifugation, extensively washed with lysis buffer without SDS, re-suspended in LDS reducing sample buffer, and boiled for 5 minutes. Proteins were separated by SDS-PAGE and transferred to PVDF membranes, which were then incubated in 10 mM Tris pH 7.4, 1 mM PMSF, 10 mM β-mercaptoethanol and 6 M guanidine for 1 hour at 4 °C, followed by extensive washing in PBS. Membranes were then incubated with primary antibodies diluted in blocking buffer (2% fat free milk in PBS) overnight at 4 °C. After extensive washing, the membranes were then incubated with secondary HRP-conjugated antibodies and developed using SuperSignal West Femto Maximum Sensitivity Substrate or West Pico (Thermo-Fischer Scientific, IL). Mouse anti-Ubiquitin (Santa Cruz biotechnology, CA) and mouse anti-HA (Clone A1, Covance) antibodies were diluted at 1:1000; mouse anti-αkap (clone A1, Santa Cruz biotechnology) was diluted at 1:200; rabbit anti-CaMK-II (M176, Santa Cruz biotechnology) was diluted at 1:500; rabbit anti-GFP and rat anti-AChRα. MAB 210 (Covance) were diluted at 1: 5000; Mouse anti-tubulin (The Developmental Studies Hybridoma Bank, Iowa) was diluted 1:10000; rabbit anti-Lrp4 was diluted 1:10000, anti-LAMP1 was diluted 1:1000; anti-P2X2 was diluted 1:5000. All horseradish peroxidase-conjugated secondary antibodies (Jackson ImmunoResearch) were diluted at 1:10000.

The intensity of bands on Western blots was quantified by scanning the film at 8 bits with white assigned a value of 0 and black a value of 255. We then conducted the analysis using Image J (Version 1.45). We first verified that there was no saturation in the darkest regions of the blot, and then selected a region of the film with no signal, which was used to calculate a background level that was subtracted from all pixel values so that the subtracted baseline was assigned a value of 0. We then used the “magic wand” function to select the pixels of each band, and the measure function to determine the integrated intensity of the selected region. This value is linearly proportional to the amount of reaction product imaged on the film, but not necessarily to the amount of protein present. For all data presented as
Electrophysiology

HEK293T cells were co-transfected with either all four wild type AChR subunits (α, β, δ, and ε) or the 4R mutant of α and wild type β, δ, and ε). Each transfection mix also included a plasmid encoding EGFP.

Whole cell recordings from green fluorescent cells were made approximately 48 hr after transfection, using a Dagan 3900 patch clamp (Minneapolis MN) and Clampex 9.0 software (Molecular Devices, Sunnyvale CA). All recordings were made at room temperature with the holding potential set to −50 mV. The perfusion solution was switched from extracellular solution alone to extracellular solution plus acetylcholine with a BPS8 solution switcher (ALA, East Farmingdale NY). The cell was perfused by solutions applied from a narrow bore pipette placed about 1 mm from the cell. The 10–90% exchange time of this system was approximately 25 ms.

The extracellular recording solution contained 135 mM NaCl, 1.5 mM KCl, 1 mM CaCl₂, 1 mM MgCl₂ and 15 mM HEPES (pH 7.5). The intracellular solution contained 140 mM KCl, 1 mM MgCl₂, 10 mM EGTA and 10 mM HEPES pH 7.5.

RESULTS

Acetylcholine receptors form complexes with αkap

Previous studies have shown that αkap is able to directly interact with many CaMK-II isoforms (Bayer et al., 1996; Bayer et al., 2002), and since CaMK-II has been shown to control the density of AChR at the mature NMJ (Martinez et al., 2010), we asked whether αkap could be involved in this process. To test this idea, lysates from cultured C2C12 myotubes were incubated with α-bungarotoxin-biotin (BTX-biotin) to label AChR and then AChR-BTX-biotin complexes were isolated with NeutrAvidin-coated beads and subjected to Western blot analysis with anti-AChR α and anti-αkap antibodies. αkap was pulled down with AChR α (Figure 1A), indicating that AChRs are present in the same complex with αkap. Similarly, when calmodulin coated beads were used, we also pulled down AChR α with αkap (Fig 1B). It should be noted that neither AChR nor αkap have calmodulin binding sites, indicating that the pull down by calmodulin beads is indirect, presumably due to the known ability of αkap to bind to multiple calmodulin-binding CaMK-II isoforms. Thus proteins besides AChR α and αkap are present in the material pulled down from cells that endogenously express both proteins. The interaction of αkap and AChR α was also observed when HEK293T cells (which lack endogenous αkap and AChR subunits) were co-transfected with AChR α and HA-tagged αkap constructs (Figure 1D). AChR α was not pulled down by anti-HA coupled agarose beads when it was expressed alone but both αkap and AChR α were present in the lysate that was pulled down by anti-HA when cells were co-transfected. This result suggests that either αkap directly interacts with AChR α or other components of the complex that link these two proteins are expressed in both muscle and HEK293T cells.

Knockdown of αkap decreased AChR protein levels

Having demonstrated that αkap is present in a complex with AChR α, we next tested whether changing the expression of αkap had an effect on the clustering of AChR on the muscle cell surface. To do this, we used αkap specific short-hairpin RNA (shRNA) to knock down the expression of αkap in C2C12 muscle cells. We designed two different shRNAs (shRNA137 and shRNA337), and as an initial test of the efficiency of the knock down, we
transfected C2C12 myoblasts with GFP-αkap alone or co-transfected with GFP-αkap and either shRNA137 or 337. When myotubes were viewed 4–5 days later, there were many green fluorescent fibers in the dishes transfected with GFP-αkap alone, but very few fluorescent fibers in the dishes co-transfected with GFP-αkap and shRNAs (data not shown), indicating that both shRNAs were effective in knocking down the expression of exogenous αkap-GFP. Western blot analysis of equal amount of proteins with anti-αkap antibody showed that transfection with either shRNA drastically reduced the endogenous expression of αkap protein as compared to untransfected myotubes or myotubes transfected with a scrambled shRNA (Fig 2A). In contrast, neither of the shRNAs had an effect on the expression level of three CaMK-II isoforms (β, γ and δ) that have several domains similar to domains of αkap (Fig 2A). We performed all remaining experiments using shRNA337, which will be referred to as shRNA(αkap).

Next we examined the effect of the knockdown of αkap on AChR clusters on the surface of muscle cells. C2C12 myoblasts were co-transfected with plasmids encoding EGFP and either shRNA(αkap) or its scrambled version and grown on laminin coated dishes. The AChR clusters (identified by their labeling with fluorescent BTX) were fewer and smaller on myotubes transfected with shRNA (identified by their labeling with EGFP) compared to either untransfected myotubes in the same dish (Figure 2B), or to myotubes in separate dishes transfected with the scrambled shRNA alone (data not shown). The average percentage of the surface covered by clustered receptors in control myotubes was 6.8% ± 3.3% but this fell to 0.7% ± 0.2% in ShRNA(αkap) knockdown myotubes (±SEM, N=10 fibers each).

The decrease in the number of clusters of AChR on the surface of myotubes transfected with shRNA could have been produced by several mechanisms. The morphology of cultured myotubes co-transfected with EGFP and shRNA(αkap) plasmids was indistinguishable from untransfected myotubes, indicating that αkap knockdown had no effect on the differentiation of myoblasts into myotubes. Since AChR forms a complex with several other postsynaptic proteins, another possibility was that depletion of αkap might lead to a decrease in other components of the complex that are involved in receptor clustering. However, Western blot results showed that shRNA(αkap) produced a dramatic decrease in AChRα, but no change in the level of the AChR clustering protein rapsyn (Fig. 3A). We next tested whether the decrease in the amount of AChRα was due to a decrease in AChR mRNAs. However, when RT-PCR products specific to AChRα were analyzed (Figure 3B), we found that there was no difference in the amount of AChRα mRNAs between untransfected and αkap depleted myotubes. If αkap is involved specifically in clustering AChR on the surface of myotubes, the amount of AChR on the plasma membrane should be the same in myotubes transfected with shRNA(αkap) and scrambled shRNA and in untransfected myotubes. However, in myotubes transfected with shRNA(αkap), the amount of surface AChRα was dramatically reduced compared to scrambled or untreated myotubes (Figure 3C, D). We also found that fewer receptors were detected in the internal pool of myotubes transfected with shRNA(αkap) compared to myotubes transfected with scrambled shRNA or to control myotubes (Figure 3E, F). Thus both the intracellular and the surface pools of AChRα were depleted by similar amounts.

akap controls AChR degradation

Having shown that knockdown of αkap has no effect on mRNA levels for AChRα but drastically reduced AChRα protein levels, we hypothesized that αkap might control the stability of AChR. As an initial test, muscle cells were treated with MG132, a widely used proteasome inhibitor that can prevent degradation of many ERAD substrates (Rock et al., 1994) or with leupeptin, a lysosome inhibitor. We found that in untransfected myotubes or myotubes transfected with the scrambled shRNA, both MG132 and leupeptin increased the

J Neurosci. Author manuscript; available in PMC 2012 October 11.
amount of AChRα protein to approximately 160% of the untreated control (Figure 4), indicating that both inhibitors were able to prevent AChRα degradation. However, the two inhibitors had quite different effects on C2C12 myotubes that had been transfected with shRNA(αkap). The effect of MG132 on cells transfected with shRNA(αkap) was quite similar to the effect of MG132 on untransfected cells (Figure 4A, B), while the effect of leupeptin plus shRNA(αkap) was quite similar to shRNA(αkap) alone (Figure 4C, D). Thus, in the presence of shRNA(αkap), MG132 produced an average increase of 578% ± 16% in AChRα, while leupeptin produced no change (95% ± 8%). A second pair of inhibitors showed similar trends. In the presence of shRNA(αkap), the proteasome inhibitor lactacystin produced a significant increase in AChRα (average of 333% ± 62%, P<0.05, n=4), but the lysosomal inhibitor chloroquine produced no significant increase in AChRα (average of 161 ± 47%, p>0.7). These results suggest that αkap protects AChR from degradation by the proteasome, but not from degradation within lysosomes.

To better understand the mechanism by which αkap controls the amount of AChR in myotubes, we used heterologous expression in HEK293T cells, which lack endogenous αkap and AChRα. First we tested whether αkap promotes the stability of AChRα in HEK293T cells, as it does in cultured myotubes. Lysates from cells transfected with EGFP and AChRα with or without αkap were immunoblotted with anti-AChRα antibody and AChRα levels were compared. The amount of AChRα was nearly 3 fold higher in cells co-transfected with αkap compared to cells transfected with only AChRα, indicating that αkap promotes the stability of AChR in HEK293T cells (Figure 5A, C). Treatment of HEK293T cells expressing AChRα and a control plasmid with MG132 also increased AChRα levels by about 3 fold compared to untreated control cells (Figure 5A, B, C). However, the combined effect of αkap and MG132 on AChRα accumulation was no larger than either treatment alone, indicating that αkap is sufficient to maximally protect AChRα from degradation by the proteasome (Figure 5C).

Next, we tested whether αkap is involved in controlling the stability of other AChR associated components expressed in HEK293T cells. In contrast to AChRα, the amount of α-syntrophin or α-dystrobrevin (two components of the postsynaptic dystrophin glycoprotein complex that tethers AChR) was similar in the presence or absence of αkap (Figure 5D). However, like AChRα, the amount of Lrp4 (low-density lipoprotein receptor–related protein 4), a transmembrane protein that transmits a signal required for clustering of AChRs, was significantly higher in cells co-transfected with αkap (190% ± 10% of the level in cells transfected with Lrp4 only, n=4, Figure 5E). To explore the possibility that αkap might be acting as a general regulator of the stability of transmembrane proteins, we tested two additional transmembrane proteins expressed in HEK293T cells. Neither rat P2X2 (a plasma membrane protein) nor LAMP1 (a lysosomal membrane protein) was sensitive to the presence of αkap (Figure 5E). Thus, αkap is not a general regulator of transmembrane proteins.

Previous studies have shown that in several cell types αkap is largely localized to the ER compartment (Nori et al., 2003; Singh et al., 2009) and that when AChRα is expressed without other AChR subunits, it remains mostly trapped in the ER (Christianson and Green, 2004). We therefore examined whether AChRα co-localizes with αkap in the ER of HEK293T cells. Confocal microscopy analysis of cells co-transfected with monomeric GFP-αkap, AChRα, and the ER marker mCherry-PdiA 3 showed that they all reside in the ER under these conditions (Figure 5E).

Because MG132 does not promote any further AChR accumulation when αkap is present, we hypothesized that αkap might prevent ubiquitination of AChRα and thus degradation. As a first test of this hypothesis, we co-transfected HEK293T cells with AChRα and HA-
tagged ubiquitin (HA-Ub) (Fang and Kerppola, 2004) in the presence or absence of αkap and estimated the amount of AChRα in each sample by Western blots (Figure 6A). We then used this information to equalize the amount of AChRα (Figure 6B), which was then immunoprecipitated with AChRα antibody and probed on an immunoblot with anti-ubiquitin antibody. The blots showed a smear, representing the addition of several ubiquitin moieties to the various lysine residues within AChRα (Figure 6C). By quantifying the intensity of the staining in the smear, we found that when AChR was expressed alone, the level of AChRα ubiquitination was substantially higher (210% ± 10%) than when it was coexpressed with αkap.

There are four lysines (K359, K374, K388 and K393) within the major intracellular loop of AChRα that are predicted to be ubiquitinated (Radivojac et al., 2010). If the absence of αkap promotes ubiquitination of lysine residues on AChRα leading to AChR degradation, changing lysine to arginine residues (so ubiquitin cannot be conjugated) should lead to less degradation of AChRα. To directly test this idea, we used site directed mutagenesis to make four single mutant constructs (K359R, K374R, K388R, or K393R, 1R), a construct that contained three mutations [K359R/K388R/K393R, 3R], and a construct that had all four mutations (K359R/K374R/K388R/K393R, 4R). When co-expressed with HA-Ub in HEK293T cells, the 3R and 4R AChRα mutants exhibited a large decrease in ubiquitination compared to the wild-type AChRα or any of the four 1R mutants (Figure 7A, data for only one of the 1R mutants is shown). The 4R mutant AChRα was capable of assembling into a functional AChR complex when co-expressed with β, δ and ε subunits (Fig 7B). However, we decided not to pursue an electrophysiological approach to assess expression levels, because of the highly variable extent of transfection and because the rapid desensitization to maximal concentrations of ACh made the amplitude of the peak currents dependent on the position of the drug application pipette and the rate of flow out of it, as well as on the number of receptors present. When a biochemical approach was used to assess expression levels, the reduced levels of ubiquitination in the 3R and 4R mutants correlated with a significant increase in the stability of AChRα mutants compared to wild-type (Figure 7C, D). These results demonstrate that lysines 359, 374, 388 and 393 represent major sites for ubiquitination, and that ubiquitinating several of these lysines promotes degradation. The presence of αkap did not increase the amount of 3R or 4R mutants compared to wild type AChRα (Figure 7E, F) suggesting that the effect of αkap on AChRα stability is mediated by controlling AChRα ubiquitination.

Discussion

In this work we provide evidence for a novel function of αkap in controlling AChR stability. We demonstrated that 1) loss of αkap drastically reduced AChR levels, leading to fewer receptor clusters on the surface of muscle cells; 2) two proteasome inhibitors largely prevented degradation of AChRα in the absence of αkap; 3) proteasome inhibition does not enhance AChRα accumulation any further in the presence of αkap; 4) the absence of αkap increased ubiquitination of AChRα; 5) major sites for lysine ubiquitination reside within the intracellular domain of AChRα; and finally 6) mutations of AChRα lysine residues required for ubiquitination slow the degradation of AChRα.

Previous studies have shown that in heterologous cells transfected with all receptor subunits, unassembled AChR subunits are rapidly degraded in the ER and that assembly into a pentameric complex is essential for protein stability (Claudio et al., 1989; Blount and Merlie, 1990). This degradation is thought to occur in the ERAD pathway where ubiquitination and the proteasome are involved, as unassembled subunits were accumulated in cells treated with proteasome inhibitors (Christianson and Green, 2004). In the present study, we demonstrated that over-expression of αkap substantially increased the amount of
unassembled AChRα in the ER of HEK cells, even when the proteasome was functioning normally. In skeletal and cardiac muscles, αkap is highly expressed and localized to the sarcoplasmic reticulum (Nori et al., 2003; Singh et al., 2009). It was previously established that αkap associates with multiple CaMK-II isoforms and anchors them to the sarcoplasmic reticulum through its hydrophobic domain (Campbell and MacLennan, 1982; Damiani et al., 1995; Bayer et al., 1998). This has the functional consequence of modulating Ca2+ release from the sarcoplasmic reticulum and so regulating excitation/contraction coupling in muscle cells (Bers, 2002a, b). Our work indicates that αkap has a second important function as a regulator of AChR stability in muscle cells. The action of αkap on protein stability was not unique to AChR, as at least one additional muscle protein (Lrp4) was also αkap sensitive. However, two other transmembrane proteins (P2X2 and LAMP1) and the intracellular synaptic proteins (rapsyn, α-dystrobrevin and α-syntrophin) were αkap insensitive. Thus it is possible that modulation of αkap activity in vivo might have relatively selective actions on synaptic function.

The present experiments show that αkap interacts with AChRα and promotes their stability, and that the effect of αkap can be mimicked by elimination of ubiquitin conjugating sites from AChRα. How could αkap be linked to AChR stability? One possible molecular mechanism would be an indirect effect, with αkap acting as a chaperone to promote the forward trafficking of the AChR to the Golgi so that the receptors are not in the ER long enough to be modified. A second possibility is that αkap more directly regulates the state of ubiquitination of AChRα in the ER. Our results favor the latter possibility, since in HEK cells expressing AChRα alone, there is no movement to the Golgi, and yet αkap still is effective. As far as how αkap might act on AChR within the ER, one possibility is that αkap may act as a deubiquitinase. This seems unlikely because αkap does not share any similarities with known deubiquitinases. A related possibility is that αkap may control AChR deubiquitination through an association with deubiquitinase(s). It has been reported that the ubiquitin-specific protease (USP)19 localizes in the ER, and is involved in processing ERAD substrates (Hassink et al., 2009). Interestingly, Usp19 also interacts with CaMK-II (Sowa et al., 2009) and since αkap forms complexes with CaMK-II, it is possible that αkap may function as a scaffold for Usp19. Other mechanisms by which αkap could decrease ubiquitination of AChR would be by inhibiting the E3 ubiquitin ligase(s) that conjugate ubiquitin to lysines on the receptors or by masking the lysines of AChRα so they cannot be ubiquitinated.

Recent studies have shown that the ubiquitin–proteasome system is involved in regulating synaptic protein turnover and synaptic efficacy at a variety of synapses (Ehlers, 2003; Speese et al., 2003; Christianson and Green, 2004; Mabb and Ehlers, 2010). Ubiquitination has been shown to play a key regulatory mechanism for many cell surface proteins, in addition to its classical function of targeting cytosolic proteins for degradation by the proteasome. For example, ubiquitination of AMPA receptors, NMDA receptors, and PSD scaffold proteins has emerged as the major mechanism for controlling the accelerated turnover and decreased amounts of receptor proteins and thus synaptic plasticity (Juo and Kaplan, 2004; Mabb and Ehlers, 2010). At the fly NMJ, a balance between ubiquitination and deubiquitination plays a key role in shaping the morphology of the synapse. Loss of function of the ubiquitin-specific protease highwire, or its orthologue in C. elegans (rpm-I) produces profound defects in synaptic transmission (Schaefer et al., 2000; Wan et al., 2000). At developing mammalian NMJ, ubiquitination of the receptor tyrosine kinase MuSK leads to a reduction in postsynaptic MuSK expression levels and consequently defective synapses (Lu et al., 2007). Our results indicate that an additional mechanism by which ubiquitination regulates receptor trafficking in an αkap dependent manner is critical for maintaining the steady state of the postsynaptic receptor density and thus synaptic strength.
Acknowledgments

This work was supported by grants from the National institute of Health (NS-047332). The anti-AChR (mab35) antibodies were obtained from the Developmental Studies Hybridoma Bank. We thank Dr. Stephan Kröger and his group for providing antibodies and Lrp4 construct and members of our lab for their comments on the manuscript.

References


J Neurosci. Author manuscript; available in PMC 2012 October 11.


Weatherbee SD, Anderson KV, Niswander LA. LDL-receptor-related protein 4 is crucial for formation of the neuromuscular junction. Development. 2006; 133:4993–5000. [PubMed: 17119023]


Figure 1. αkap forms complexes with AChR in skeletal muscle cells

(A) Lysates from cultured C2C12 myotubes were incubated with (+ BTX) or without (− BTX) BTX-biotin and then biotin containing complexes were isolated with NeutrAvidin beads. Pull down proteins were probed with anti-αkap or anti-AChRα antibody. (B) Myotube lysates were incubated with Calmodulin beads in the absence of calcium (− Ca) or in the presence 2 mM calcium (+ Ca) to pull down Calcium/Calmodulin binding proteins. Blots were probed with anti-αkap or anti-AChRα antibody. (C) Lysates from human embryonic kidney (HEK293T) cells transfected with AChRα and αkap-HA (+ αkap) or with AChRα and empty plasmid (−αkap) were immunoprecipitated with anti-HA coupled-agarose beads and blots were probed with anti-αkap or anti-AChRα antibodies. (D) Aliquots from the lysates used for the pull downs in panel C probed for tubulin. For all four panels, at least three independent experiments were performed.
Figure 2. Knockdown of αkap significantly reduced the formation of AChR clusters on the surface of muscle cells
C2C12 myoblasts were transfected with either shRNA(αkap) or scrambled shRNA and then 4 to 5 days after their differentiation, myotubes were either harvested for protein extraction and immunoblotting, or bathed with BTX-Alexa594 to label surface AChR. (A) Western blots of equal amount of proteins from untransfected myotubes (Cont), myotubes transfected with shRNA(αkap) (a plasmid expressing shRNA specific to αkap), or a plasmid containing a scrambled version of the shRNA sequence (Scram). Blots were probed with anti-αkap or anti-CaMK-II (M176) antibody. M176 recognizes multiple CaMK-II isoforms, including three that are expressed in skeletal muscle (βm, δ, and γ). Tubulin was used as loading.

(A) Western blots of equal amount of proteins from untransfected myotubes (Cont), myotubes transfected with shRNA(αkap) (a plasmid expressing shRNA specific to αkap), or a plasmid containing a scrambled version of the shRNA sequence (Scram). Blots were probed with anti-αkap or anti-CaMK-II (M176) antibody. M176 recognizes multiple CaMK-II isoforms, including three that are expressed in skeletal muscle (βm, δ, and γ). Tubulin was used as loading.

(B) Immunostaining of AChR and GFP-shRNA (αkap) in myotubes.
control. (B) Untransfected myotubes (arrows) and a myotube transfected with GFP-shRNA(αkap) viewed in the same dish to allow comparison of the number of AChR clusters when αkap is knocked down. Very few clustered receptors were present on transfected (green fluorescent, arrowhead) myotubes.
Figure 3. Knockdown of αkap reduced AChR protein levels

(A) Equal amounts of proteins from lysates of myotubes transfected with shRNA(αkap) or scrambled shRNA (Scram) or untransfected myotubes (Cont) were probed with four antibodies to assess the effect of the shRNA on αkap, AChRα, rapsyn and tubulin. (B) RT-PCR products of AChRα from cultured myotubes transfected with shRNA(αkap), scrambled shRNA and untransfected myotubes. The PCR reaction conditions did not allow saturation to be reached for any of the samples, so band intensity is proportional to the amount of mRNA in the original sample. (C) Western blots of surface AChRα. Living myotubes were treated with BTX-biotin at 4 °C to saturate all surface receptors prior to cell lysis. Biotin labeled surface AChR were precipitated with NeutrAvidin beads. AChRα-
subunits were detected with MAB210. (D) Quantification of 3 blots as in C. (E) Western blots of intracellular AChRα. Surface receptors were saturated with unlabeled BTX, and then muscle lysates were saturated with BTX-biotin to selectively label intracellular AChR. (F) Quantification of 3 blots as in E.
Figure 4. A proteasome inhibitor prevented AChR degradation in cells transfected with
shRNA(αkap)

(A) Myotubes transfected with shRNA(αkap), scrambled shRNA, or untransfected
myotubes were treated with the proteasome inhibitor MG132 (at 5 µM) and lysates were
immunoblotted with MAB210 antibody against AChRα. Tubulin was used as a loading
control. (B) Quantification of 3 independent experiments as in A. 100% was the average
intensity of the samples from untransfected myotubes in the absence of MG132. (C)
Myotubes transfected with plasmids encoding shRNA(αkap) or the scrambled shRNA were
treated with leupeptin (20 µg/ml). (D) Quantification of three independent experiments as in
C. 100% was the average intensity of the samples from myotubes transfected with the
scrambled shRNA in the absence of leupeptin.
Figure 5. **α**kap increased AChRα accumulation in transfected HEK cells

(A) Western blots of homogenates from HEK293T cells co-transfected with AChRα, αkap-HA and pEGFP-C3 (+) or with AChRα, pEGFP-C3 and an empty version of the same vector into which αkap-HA was inserted (−). GFP was used as a control for the transfection efficiency and for the loading of total proteins. Anti-HA antibody was used to confirm the expression of αkap. (B) Experiment identical to A, except that MG132 was present. (C) Quantification of two independent replicates of experiments as in A and B. (D) Western blots of lysates from HEK293T cells transfected with alpha syntrophin or alpha dystrobrevin with or without αkap. (E) Lysates from HEK293T cells transfected with Lrp4 or P2X2 with or without αkap were probed with antibodies against Lrp4, P2X2 and LAMP1. (F) Confocal
images of a HEK293T cell co-expressing GFP-αkap, AChRα, and PdiA-mcherry (a marker of the ER). The nucleus was labeled with DAPI. Cells were fixed, permeabilized and stained with anti-AChR antibody (MAB 35) followed by anti-rat Alexa647 labeled secondary antibody to visualize AChR. PdiA and αkap were visualized by the fused fluorescent proteins.
**Figure 6. αkap inhibits ubiquitination of AChRα.**

Two independent replicates are shown in all three panels. A) The level of expression of AChRα in lysates from HEK293T cells co-transfected with AChRα, HA-tagged ubiquitin (HA-Ub) and either a plasmid encoding αkap (+) or empty vector (−) as a control. Tubulin staining (not shown) indicated that equal amounts of protein were loaded in the two lanes. (B, C) Lysates with equal amounts of proteins were immunoprecipitated with anti-AChRα antibody (MAB153) and probed with AChRα antibody MAB210 (B) or with anti-ubiquitin antibody (C). To allow the amount of ubiquitination to be easily compared between experimental conditions, prior to the immunoprecipitation step the concentration of total proteins in each sample was adjusted so that similar amounts of AChRα would be...
precipitated (see B) even though the amounts of AChR in the original samples were quite different (see A). The material recognized by anti-ubiquitin appears as a smear because the extent of polyubiquitination varies widely.
Figure 7. αkap had no effect on the stability of AChRα when lysines essential for ubiquitination were mutated

HEK293T cells were co-transfected with plasmids encoding the indicated AChRα variants and HA-Ubiquitin and 48 hours later protein lysates were collected. The anti-AChRα antibody MAB153 was used to selectively immunoprecipitate proteins from each sample. (A) The extent of ubiquitination of AChRα detected with an anti-HA antibody. In this experiment, the amount of material loaded onto each lane was adjusted so that comparable amounts of AChRα were present in all samples. The top gel shows the amount of AChRα detected with anti-AChRα (MAB210), and the bottom gel shows the anti-HA immunoreactivity. The control lane (Cont) was from cells transfected with HA-Ub only. The
1R lane is the K359R mutant, the 3R lane is the K359R/K388R/K393R mutant and the 4R lane is the K359R/K374R/K388R/K393R mutant. The lower band present in all lanes of the anti-HA blot (arrow) is the 25 kD light chain of the antibody used for immunoprecipitation and served as a loading control. The smear present in some lanes (brackets, approximately 70–250 kD) is polyubiquitinated AChRα, and so is absent in the control because no AChR were present. Polyubiquitination of AChRα was greatly decreased in the 3R and 4R mutants. (B) Whole cell recordings from HEK293T cells co-transfected with EGFP, wild type AChR β, δ and ε subunits and either the wild type or the 4R mutant AChRα. The holding potential was −50 mV. ACh was applied for the duration indicated by the bar above each trace. (C) Western blots of homogenates from HEK293T cells co-transfected with EGFP and wild-type AChRα or the ubiquitination deficient 3R or 4R mutant. In these experiments, the same amount of material (as determined from anti-GFP staining) was loaded onto each lane. No αkap was present (− αkap) (D) Quantification of three independent experiments similar to C. In this panel as well as panel F, 100% represents the intensity of signal produced when cells were transfected with wild type AChRα in the absence of αkap. E) Experiment similar to C, except that the cells were also co-transfected with a plasmid encoding αkap (+ αkap). F) Quantification of three experiments similar to E.